|
cervical cancer |
18 |
|
intravoxel incoherent motion |
16 |
|
pet/ct |
14 |
|
diffusion-weighted imaging |
12 |
|
magnetic resonance imaging |
12 |
|
ovarian cancer |
10 |
|
standardized uptake value |
10 |
|
contrast-enhanced ct |
9 |
|
perfusion |
9 |
|
diffusion magnetic resonance imaging |
8 |
|
radiomics |
8 |
|
18f-fdg pet/ct |
7 |
|
curriculum |
7 |
|
medical students |
7 |
|
observer variation |
7 |
|
uterine cervical neoplasms |
7 |
|
adenocarcinoma |
6 |
|
bone marrow |
6 |
|
chemoradiotherapy |
6 |
|
concurrent chemoradiotherapy |
6 |
|
dce-mri |
6 |
|
ivim |
6 |
|
non-small cell lung cancer |
6 |
|
positron emission tomography |
6 |
|
prognostic factor |
6 |
|
18f-fdg pet |
5 |
|
abdominal pregnancy |
5 |
|
aorta |
5 |
|
carcinosarcoma |
5 |
|
ectopic pregnancy |
5 |
|
female |
5 |
|
gestational trophoblastic neoplasia |
5 |
|
head and neck cancer |
5 |
|
hemoperitoneum |
5 |
|
imbalanced datasets |
5 |
|
interval debulking surgery |
5 |
|
leiomyosarcoma |
5 |
|
lymph node metastasis |
5 |
|
mri |
5 |
|
neo-adjuvant chemotherapy |
5 |
|
peritoneal carcinomatosis |
5 |
|
re-sampling techniques |
5 |
|
uterine sarcoma |
5 |
|
2-[18f]fdg pet/ct |
4 |
|
acute leukemia |
4 |
|
bone marrow - drug effects - pathology - radionuclide imaging |
4 |
|
chemotherapy response score |
4 |
|
classification of proteins |
4 |
|
diagnostic procedure |
4 |
|
diffusion measurement |
4 |
|
diffusion mri |
4 |
|
egfr mutations |
4 |
|
extramedullary |
4 |
|
fdg pet/ct |
4 |
|
fdg-pet/ct |
4 |
|
fluorodeoxyglucose f18 - diagnostic use |
4 |
|
hands-on training |
4 |
|
hematological toxicity |
4 |
|
humans |
4 |
|
ileal neoplasms - drug therapy - pathology - radionuclide imaging |
4 |
|
indolent lymphoma |
4 |
|
learning |
4 |
|
lymphoma |
4 |
|
male |
4 |
|
marrow biopsy |
4 |
|
medical imaging |
4 |
|
medicine |
4 |
|
monomorphic epitheliotropic intestinal t cell lymphoma |
4 |
|
myeloid sarcoma |
4 |
|
neoadjuvant chemotherapy |
4 |
|
neoplasia |
4 |
|
neoplasm staging |
4 |
|
neoplasm, residual |
4 |
|
omics |
4 |
|
ovarian neoplasms |
4 |
|
peritoneal neoplasms |
4 |
|
point-of-care ultrasound |
4 |
|
positron emission tomography computed tomography |
4 |
|
positron-emission tomography and computed tomography |
4 |
|
positron-emission tomography and computed tomography - methods |
4 |
|
radiation therapy |
4 |
|
radiopharmaceuticals - diagnostic use |
4 |
|
sarcoma, myeloid - drug therapy - pathology - radionuclide imaging |
4 |
|
sarcoma, myeloid - pathology - radionuclide imaging |
4 |
|
sensitivity and specificity |
4 |
|
stage iv |
4 |
|
suv |
4 |
|
suvmax |
4 |
|
teaching |
4 |
|
ultrasonography |
4 |
|
ultrasound |
4 |
|
acute kidney injury |
3 |
|
adc |
3 |
|
area under the curve |
3 |
|
b-values |
3 |
|
biomarker |
3 |
|
cervical carcinoma |
3 |
|
contrast media |
3 |
|
cranial nerves |
3 |
|
cytoreduction |
3 |
|
deauville score (ds) |
3 |
|
diffusion |
3 |
|
diffusion kurtosis imaging |
3 |
|
diffusion-weighted mri |
3 |
|
disease progression |
3 |
|
disease staging |
3 |
|
dwi |
3 |
|
endometrial carcinoma |
3 |
|
endovascular procedures |
3 |
|
entropy |
3 |
|
extranodal |
3 |
|
extranodal natural killer/t-cell lymphoma (enktl) |
3 |
|
fdg |
3 |
|
figo |
3 |
|
histologic subtypes |
3 |
|
histopathologic features |
3 |
|
idiopathic pulmonary fibrosis |
3 |
|
lymphoepithelioma-like carcinoma |
3 |
|
mantle cell lymphoma |
3 |
|
measurement |
3 |
|
neurolymphomatosis |
3 |
|
oral arsenic trioxide |
3 |
|
ovarian and peritoneal cancers |
3 |
|
ovarian carcinoma |
3 |
|
positron-emission tomography |
3 |
|
recurrence detection |
3 |
|
refractory |
3 |
|
relapsed |
3 |
|
response assessment |
3 |
|
response criteria |
3 |
|
squamous cell carcinoma |
3 |
|
synthetic magnetic resonance imaging |
3 |
|
tumor debulking |
3 |
|
vagus nerve |
3 |
|
18f-fdg pet/ ct |
2 |
|
asia |
2 |
|
automated segmentation |
2 |
|
chinese |
2 |
|
chronic urticaria |
2 |
|
computed tomography |
2 |
|
contrast media - diagnostic use |
2 |
|
cu-q2ol |
2 |
|
deep learning |
2 |
|
epithelial ovarian carcinoma |
2 |
|
fluorodeoxyglucose f18 |
2 |
|
garadacimab |
2 |
|
hereditary angioedema |
2 |
|
hong kong |
2 |
|
image-guided radiotherapy |
2 |
|
intensity-modulated radiotherapy |
2 |
|
lanadelumab |
2 |
|
low-rank subspace reconstruction |
2 |
|
mediation analysis |
2 |
|
mr fingerprinting |
2 |
|
multiparametric mri |
2 |
|
neoplasms - diagnosis - radiography - radionuclide imaging |
2 |
|
nuclear physics medical sciences |
2 |
|
ovarian cancer (oc) |
2 |
|
patient-reported outcome |
2 |
|
perfusion imaging |
2 |
|
peritoneal metastases |
2 |
|
pet |
2 |
|
physics |
2 |
|
prophylaxis |
2 |
|
quality of life |
2 |
|
quality-of-life |
2 |
|
radiation oncology |
2 |
|
radiology and nuclear medicine |
2 |
|
sleep |
2 |
|
technology assessment |
2 |
|
thrombosis - diagnosis - radiography - radionuclide imaging |
2 |
|
tumor thrombosis |
2 |
|
uterine cervical cancer |
2 |
|
work productivity |
2 |
|
wpai |
2 |
|
x-ray computed tomography |
2 |
|
18f-fluorodeoxyglucose-pet |
1 |
|
adolescent |
1 |
|
artifacts |
1 |
|
artificial intelligence |
1 |
|
breast cancer |
1 |
|
combined modality therapy |
1 |
|
computer-aided diagnosis (cad) |
1 |
|
ct scan |
1 |
|
dynamic contrast-enhanced magnetic resonance imaging (dce-mri) |
1 |
|
echo-planar imaging |
1 |
|
efficientnet-v2 model |
1 |
|
endometrial neoplasms |
1 |
|
epidermal growth factor receptor (egfr) |
1 |
|
evidence theory |
1 |
|
fat segmentation |
1 |
|
genital neoplasms |
1 |
|
her2 |
1 |
|
hr |
1 |
|
image interpretation, computer-assisted |
1 |
|
image signatures |
1 |
|
immunohistochemistry |
1 |
|
knee injuries - diagnosis |
1 |
|
machine learning |
1 |
|
muscle segmentation |
1 |
|
pelvis |
1 |
|
pneumococcal infections |
1 |
|
pneumonia/classification |
1 |
|
positron emission tomography/computed tomography (pet/ct) |
1 |
|
radiography, thoracic |
1 |
|
references (10) view in table layout |
1 |
|
risk factors |
1 |
|
rupture - diagnosis |
1 |
|
sarcopenia |
1 |
|
tendon injuries - diagnosis |
1 |
|
texture features |
1 |
|
uterine cervical neoplasm |
1 |
